Abstract
Background: Alzheimer’s and Parkinson’s disease represent the two most common neurodegenerative disorders, affecting an increasing number of patients worldwide. Population ageing and lack of effective therapies and biomarkers strongly contribute to the socio-economical impact of these conditions.
Message and Conclusion: The aim of the review is to present a summary of the discoveries made on the epigenetics of Alzheimer’s and Parkinson’s disease, with a special focus on the recent advances towards the identification of new targeted therapies and biomarkers. Data supporting broad spectrum and selective small-molecule inhibition of enzymes controlling DNA methylation and histone modifications are discussed in the context of Alzheimer’s and Parkinson’s disease. The results obtained from studies performed on patients samples are also mentioned, to provide a picture of the efforts made toward identification of epigenetic-based biomarkers. Finally, given the importance of non-coding RNAs in neurodegeneration, their contribution to Alzheimer’s and Parkinson’s disease will be examined, together with a brief summary of the available miRNA-based biomarker signatures for these two conditions.Keywords: Epigenetic, Alzheimer's disease, Parkinson´s disease, histone acetylation, DNA methylation, histone modification, biomarker, targeted therapy.
Current Pharmaceutical Design
Title:Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Volume: 23 Issue: 5
Author(s): Filippo Ciceri, David Rotllant and Tamara Maes
Affiliation:
Keywords: Epigenetic, Alzheimer's disease, Parkinson´s disease, histone acetylation, DNA methylation, histone modification, biomarker, targeted therapy.
Abstract: Background: Alzheimer’s and Parkinson’s disease represent the two most common neurodegenerative disorders, affecting an increasing number of patients worldwide. Population ageing and lack of effective therapies and biomarkers strongly contribute to the socio-economical impact of these conditions.
Message and Conclusion: The aim of the review is to present a summary of the discoveries made on the epigenetics of Alzheimer’s and Parkinson’s disease, with a special focus on the recent advances towards the identification of new targeted therapies and biomarkers. Data supporting broad spectrum and selective small-molecule inhibition of enzymes controlling DNA methylation and histone modifications are discussed in the context of Alzheimer’s and Parkinson’s disease. The results obtained from studies performed on patients samples are also mentioned, to provide a picture of the efforts made toward identification of epigenetic-based biomarkers. Finally, given the importance of non-coding RNAs in neurodegeneration, their contribution to Alzheimer’s and Parkinson’s disease will be examined, together with a brief summary of the available miRNA-based biomarker signatures for these two conditions.Export Options
About this article
Cite this article as:
Ciceri Filippo, Rotllant David and Maes Tamara, Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612823666170124121140
DOI https://dx.doi.org/10.2174/1381612823666170124121140 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Microenvironmental Regulation of Cancer Stem Cell Phenotypes
Current Stem Cell Research & Therapy Brain-Derived Neurotrophic Factor (BDNF) has Proliferative Effects on Neural Stem Cells through the Truncated TRK-B Receptor, MAP Kinase, AKT, and STAT-3 Signaling Pathways
Current Neurovascular Research Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease
Current Topics in Medicinal Chemistry Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice
Drug Metabolism Letters Structure, Roles and Inhibitors of a Mitotic Protein Kinase Haspin
Current Medicinal Chemistry Decision Support System for Lymphoma Classification
Current Medical Imaging Recent Advances of Metallocenes for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Cancer-Homing Toxins
Current Pharmaceutical Design Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science Polysialyltransferase: A New Target in Metastatic Cancer
Current Cancer Drug Targets Effect of Phosphorylation and Aggregation on Tau Binding to Dna
Protein & Peptide Letters Andrographolide Mitigates Unfolded Protein Response Pathway and Apoptosis Involved in Chikungunya Virus Infection
Combinatorial Chemistry & High Throughput Screening Current Research on Opioid Receptor Function
Current Drug Targets